Gilead

Medicines that Treat High Prevalence Conditions Offer Hope to Many as the Annual Drugs to Watch List from Clarivate Identifies 11 New Blockbusters Forecasted to Launch in 2020 | PR Newswire | 2/10/2020

Cortellis identifies new drugs for treating indications for breast cancer, lymphoma, multiple sclerosis (MS) and migraine touted for commercial and clinical success PHILADELPHIA and LONDON Clarivate Analytics plc (NYSE: CCC ; CCC.WS), a global leader in providing trusted insights and analytics to accelerate the pace of innovation, today announced the launch of its annual Cortellis “ Drugs to Watch “ list, which identifies 11 new drugs that are scheduled to enter the market …

Impatience with Gilead reclamation project sparks acquisition chatter | STAT | 2/10/2020

Gilead CEO Dan O’Day Emilie Pickering for STAT I n recent days, there’s been investor chatter about stalled-out Gilead Sciences ( GILD ) becoming a takeover target. The possibility that’s it’s vulnerable to acquisition even sparked a rally in its stock price last week — something the biotech’s own CEO, Dan O’Day, and his newly formed executive team couldn’t manage to do during their disappointing earnings call and 2020 outlook. So I …

Follow Gilead:    

New Strong Sell Stocks for February 10th | Zacks | 2/10/2020

… has been revised 7.6% downward over the last 30 days. KT Corporation ( KT - Free Report ) provides telecommunications services. The for its current year earnings has been revised 7.2% downward over the last 30 days. Gilead Sciences, Inc. ( GILD - Free Report ) a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs. The for its current year earnings has been revised nearly 7% downward over …

Coronavirus explained: The death toll rises to over 900, exceeding SARS and MERS | 2/10/2020

… responsible. There are no approved treatments for coronaviruses, but on February 6, China enrolled a small number of patients in a clinical trial with Remdesivir, an experimental antiviral drug from the American pharmaceutical company Gilead that has not yet been approved for use but shown promising in laboratory studies. “While there is currently no antiviral data for remdesivir showing activity against 2019-nCoV, the data available in other coronaviruses gives …

We Can Develop New Drugs Without Patent Monopolies # 54,217 | 2/10/2020

… possibility that China may require the compulsory licensing of a patent on a drug developed by Gilead, in order to produce a treatment for the Coronavirus. A compulsory license means that sacrificing the monopoly Gilead had expected, which means it will only get a small fraction of the revenue it might have otherwise anticipated. Nisen is concerned that this lost revenue will reduce expected profit in the future, meaning that …

Choroidal Neovascularization Market by Forecast to 2027 with Global Key Players – Pfizer Inc.,F. Hoffmann-La Roche Ltd. | 2/10/2020

Global Choroidal Neovascularization Market 2020 Research Report The Global Choroidal Neovascularization Market 2020 Research Report is a professional and in-depth study on the current state of Choroidal Neovascularization Market. The report provides a basic overview of the industry including definitions and classifications. The Choroidal Neovascularization The report discusses the various types of solutions for Choroidal Neovascularization Choroidal Neovascularization threats is changing the market scenario. Top Key [email protected] Pfizer Inc …

Monday’s scoreboard | 2/10/2020

… Beloit W. Branch 57, Austintown Fitch 29 Brecksville-Broadview Hts. 51, Parma Hts. Valley Forge 48 Burton Berkshire 46, Orwell Grand Valley 29 Canal Fulton Northwest 52, Akr. Manchester 33 Cardington-Lincoln 52, Mt. Gilead 40 Casstown Miami E. 41, Spring. NW 18 Chagrin Falls Kenston 63, Willoughby S. 33 Cin. Deer Park 47, Reading 39 Cin. Indian Hill 53, Cin. Wyoming 39 Cin. Mariemont 45, Cin. Madeira 32 Cin …

Svb Leerink Equities Analysts Reduce Earnings Estimates for Gilead Sciences, Inc. (NASDAQ:GILD) | 2/10/2020

Gilead Sciences, Inc. (NASDAQ:GILD) – Equities research analysts at Svb Leerink dropped their Q3 2020 earnings per share (EPS) estimates for Gilead Sciences in a research note issued on Wednesday, February 5th. Svb Leerink analyst G. Porges now anticipates that the biopharmaceutical company will post earnings of $1.60 per share for the quarter, down from their prior estimate of $1.62. Svb Leerink also issued estimates for Gilead Sciences’ FY2020 earnings …

Hepatitis C Virus And Therapeutics Market Profitable Research Report Forecast to 2027 with Global Key Players | Gilead, Johnson & Johnson, Bristol-Myers Squibb Company, Merck, and AbbVie | 2/10/2020

Reports and Markets - Monday, February 10, 2020. Hepatitis C Virus And Therapeutics Market 2020 The Global Hepatitis C Virus And Therapeutics Market 2020 Research Report is a professional and in-depth study on the current state of the Hepatitis C Virus And Therapeutics Market industry. Global Hepatitis C Virus And Therapeutics Hepatitis C Virus And Therapeutics //bit.ly/2vlbjMq Some of the key players operating in this market include: Gilead, Johnson …

How Coronavirus is Impacting Stocks of 4 Global Brands in Consumer Goods Industry | 2/10/2020

… the knowledge about the virus from 41 countries with the main interest from the people living in Vietnam, Russia, France, Mexico and Slovakia. We also discovered that Panasonic, Tesla, Contemporary Amperex Technology Limited and Gilead Sciences were the dominant brands that people wanted to know how the virus would impact their shares in various stock exchange markets. In this piece, using real time data, we explored the impact of the …

Global Liver Disease Treatment Market 2020 Sanofi, Gilead Science, Novartis AG, GlaxoSmithKline, Bayer AG, Merck & Co | 2/10/2020

… businesses, and commercial marketers. Download Free Sample Liver Disease Treatment Report : http://www.marketresearchstore.com/report/global-liver-disease-treatment-industry-market-report-2019-611096 RequestSample The Leading players mentioned in the Liver Disease Treatment Market : Sanofi, Gilead Science, Novartis AG, GlaxoSmithKline, Bayer AG, Merck & Co, F. Hoffmann-La Roche, Pfizer, Johnson &Johnson, AstraZeneca The report has unveiled fast growth in the current and previous years and is going to evolve with persistent …

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by American International Group Inc. - Ticker Report | 2/10/2020

American International Group Inc. trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,186,113 shares of the biopharmaceutical company’s stock after selling 77,916 shares during the period. Gilead Sciences makes up 1.3% of American International Group Inc.’s portfolio, making the stock …

Clark Estates Inc. NY Increases Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) | 2/10/2020

Clark Estates Inc. NY Increases Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) Posted by John Perry on Feb 10th, 2020 Tweet Clark Estates Inc. NY grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 13.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 53,000 shares of the biopharmaceutical company’s stock after acquiring an additional 6,400 shares …

Could These 5 Stocks Benefit From the Coronavirus Outbreak? | The Motley Fool | 2/10/2020

… may, in fact, get a healthy boost from this rapidly developing healthcare story in the coming week. Which biotech stocks should investors have a close eye in the days ahead? BioCryst Pharmaceuticals ( NASDAQ:BCRX ) , Gilead Sciences ( NASDAQ:GILD ) , Inovio Pharmaceuticals ( NASDAQ:INO ) , Moderna, Inc. ( NASDAQ:MRNA ) , and Novavax ( NASDAQ:NVAX ) could all make big moves this week on the coronavirus threat. Here’s what investors need to know right now. Image …

Possible Bearish Inside Day Candle Pattern Detected for Gilead Sciences (NASDAQ:GILD) | 2/10/2020

Possible Bearish Inside Day Candle Pattern Detected for Gilead Sciences (NASDAQ:GILD) 07am By Nick Russo SmarTrend’s candlestick scanner has spotted a possible bearish inside day candle pattern in Gilead Sciences ( NASDAQ:GILD ) based on the price action in the company’s shares. Today’s price range of $69.01 and $69.40 is within yesterday’s high and low of the day. This trading action often signifies indecision by bulls and bears to drive …

Gilead Loses Latest Battle Over PrEP Patents, but the Fight Goes On | 2/10/2020

Who owns the rights to PrEP? The U.S. government or the pharma giant? Print Advertisement A federal panel refused a request by pharmaceutical company Gilead Sciences to invalidate a pair of patents owned by the federal government to use Truvada as PrEP, or pre-exposure prophylaxis, to prevent HIV. As STAT News reports , the ruling from the Patent Trial and Appeals Board is a setback for Gilead but other challenges …

Lawsuit Filed By 86 Plaintiffs Who Suffered Kidney, Bone Injuries From Side Effects of Gilead HIV Drugs | 2/10/2020

… available years earlier. Each of the plaintiffs indicate that they suffered renal failure, kidney injury, bone loss, fractures or other complications associated with boen deterioration following exposure to TDF-based HIV drugs sold by Gilead in recent years, including Viread, Truvada, Atripla, Complera and Stribild. “Before Gilead began selling its first TDF drug, Viread, in 2001, Gilead knew that TDF posed a safety risk to patients’ kidneys and bones,” the …

U.S. FDA Grants Priority Review for Kite’s KTE-X19 Biologics License Application (BLA) in Relapsed or Refractory Mantle Cell Lymphoma | 2/10/2020

SANTA MONICA, Calif.–( BUSINESS WIRE )– Kite Pharma , a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) and granted Priority Review designation for KTE-X19, an investigational chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). The BLA is supported by data from the single arm …

The Top 5 Misconceptions About Life Sciences Employers | BioSpace | 2/10/2020

… organizations were the most prestigious. The results of the study showed that life sciences professionals believe the top five ideal employers are: Genentech, Pfizer, Merck, Amgen, and Novartis. Johnson & Johnson, Roche, Bristol-Myers Squibb, Gilead Sciences, and AbbVie were also highlighted within the top ten organizations. There was a stark contrast noticed between how current employees view their organization, and how outsiders perceive that same company. It was discovered that …

To Understand Iran, Look to the Handmaid’s Tale’s Gilead | Mike Fegelman | The Blogs | 2/10/2020

To better understand Iran, look to Gilead, the dystopian world that Canadian author Margaret Atwood created in The Handmaid’s Tale. Whereas Gilead is a totalitarian state resembling a Christian theonomy that overthrows the United States government, Iran is a run by an authoritarian regime that previously overthrew the monarchy of Reza Shah and that theocratically rules by what it considers is “divine Islamic law.” In Gilead, as in Iran, the …

Mental Health

Madison art students work with Middletown mental health agency for portrait project - GreenwichTime | 2/8/2020

… Daniel Hand High School art students from two classes — many in the AP program — drew portraits of clients at Middletown’s Gilead Community Services, as well as some of themselves for a project which will be … more Photo: Contributed Photo Madison art students work with Middletown mental health agency for portrait project 1 / 12 Back to Gallery A collaborative project in which shoreline high school art students tackle the issue of …

Madison art students work with Middletown mental health agency for portrait project - StamfordAdvocate | 2/8/2020

… Daniel Hand High School art students from two classes — many in the AP program — drew portraits of clients at Middletown’s Gilead Community Services, as well as some of themselves for a project which will be … more Photo: Contributed Photo Madison art students work with Middletown mental health agency for portrait project 1 / 12 Back to Gallery A collaborative project in which shoreline high school art students tackle the issue of …

Clinical Research

Coronavirus: New suspected cases on decline in China | 2/6/2020

Gilead Sciences, is in phase two and three clinical research into its effectiveness against the Ebola virus in Congo. In order to protect national interest, the institute said that it applied to patent the discovery of Remdesivir effectiveness to deal with the 2019-nCov and would apply for patents in other countries and regions through the Patent Cooperation Treaty. The institute called for foreign companies to withhold enforcing lawful patent …

Coronavirus unabated tolls 564 | 2/6/2020

Gilead Sciences, is in phase two and three clinical research into its effectiveness against the Ebola virus in Congo. In order to protect national interest, the institute said that it applied to patent the discovery of Remdesivir effectiveness to deal with the 2019-nCov and would apply for patents in other countries and regions through the Patent Cooperation Treaty. The institute called for foreign companies to withhold enforcing lawful patent …

Population Health

Fibrosis linked with mortality, liver-related morbidity risk in patients with NAFLD | 2/6/2020

… regardless of confounding factors and in patients with NASH, according to study results. Rod S. Taylor, MSc, PHD, chair of population health research at the University of Glasgow, and colleagues wrote that it is widely … NASH.”– by Alex Young Disclosure: Taylor reports receiving funding from Gilead. Please see the full guidelines for all other authors’ relevant financial disclosures. Biopsy-confirmed fibrosis was associated with risk for mortality and liver-related …

Role of Business Models in Funding the Biotech Industry: Global Trends and Challenges for Cuban Biotechnology | 2/5/2020

… advances. Examples include Denali Therapeutics, Jounce Therapeutics, Delinia Pharmaceuticals and Kite Pharma. In August 2018, Kite Pharma was sold to Gilead for US$11.9 billion after having absorbed repeated investments from various venture capital funds … its innovation, as well as its ability to contribute to population health in Cuba. The sector is characterized by early dedication to completing the product development cycle, taking a product from laboratory to market, thus …

Regenerative Medicine

Vineti Completes $35 Million in Series C Financing to Industrialize Personalized and High-Value Therapeutics | Globe Newswire | 2/5/2020

… 2020 07:30 ET Source: Vineti A coalition of strategic industry leaders – including Cardinal Health, Novartis Pharma AG, and Kite, a Gilead Company (Gilead Sciences, Inc.) – joins the company’s existing investor syndicate to accelerate commercial reach … could enroll almost 60,000 patients , according to the Alliance for Regenerative Medicine. “Those of us with experience in personalized therapeutics understand that innovative technology is required to support breakthrough science,” said Joe DePinto, President of …

Digital Health

HIV vaccine fails in a blow to the public health community | Fortune | 2/4/2020

… put things in perspective. Read on for the rest of the day’s news. Sy Mukherjee [email protected] @the_sy_guy DIGITAL HEALTH \n Broken genes and schizophrenia. A new study reported by the journal Nature … it comes to developing effective treatments. ( Nature ) \n INDICATIONS \n Gilead’s foray into a coronavirus vaccine. The coronavirus story has been evolving minute to minute. On the vaccine development front, however, Gilead appears to have …

How 5 top drugmakers are racing to develop cures and vaccines for the coronavirus that has killed more than 400 people and infected over 20,000 | Business Insider | 2/4/2020

… leading drugmakers have begun researching treatments and vaccines to stop the virus. In recent days, Johnson & Johnson, Regeneron Pharmaceuticals, GlaxoSmithKline, Gilead Sciences, and Moderna have all announced efforts to combat the virus. The virus’ rapid … for additional vaccine proposals with a February 14 deadline. Featured Digital Health Articles …

American College of Rheumatology

Start with Anti-TNF in RA? Not So Fast | 1/31/2020

… was no significant difference (94% vs 89%, OR 1.88, 95% CI 0.43-8.18). Similarly, 20% improvements on the criteria of the American College of Rheumatology were seen in 75% of the etanercept group compared with 55 … Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Celgene, Cyxone, Daichii, Eisai, Galapagos, Gilead, GlaxoSmithKline, Janssen, Regeneron, Roche, and Takeda. 1969-12-31T19:00:00-0500 …

Patients with moderate PsA disease more likely to meet treatment targets with apremilast | 1/23/2020

… Medical Center and the University of Washington School of Medicine, and colleagues wrote. “In this regard, treat-to-target and American College of Rheumatology recommendations for PsA support the use of the Disease Activity Index … Bristol-Myers Squibb, Celgene Corporation, Corrona, Eli Lilly, Galapagos, Genentech, Gilead, Janssen, Merck, Pfizer, Sun Pharmaceutical and UCB; and speaking fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene Corporation, Genentech, Janssen, Novartis, Pfizer and UCB …

Clinical Collaboration

Kiniksa Announces Pipeline Progress and Reiterates 2020 Clinical Data Readouts | Globe Newswire | 1/13/2020

Gilead company (Kite), recently announced a clinical collaboration evaluating the investigational combination of Yescarta ® (axicabtagene ciloleucel) and mavrilimumab in relapsed or refractory large B-cell lymphoma. The objective of the study is to determine the effect of mavrilimumab on the safety of Yescarta. Preclinical evidence shows the potential for interruption of granulocyte macrophage colony stimulating factor (GM-CSF) signaling to disrupt chimeric antigen receptor T (CAR T) cell-mediated inflammation …

Kiniksa Announces Pipeline Progress and Reiterates 2020 Clinical Data Readouts - GuruFocus.com | 1/13/2020

Gilead company (Kite), recently announced a clinical collaboration evaluating the investigational combination of Yescarta ® (axicabtagene ciloleucel) and mavrilimumab in relapsed or refractory large B-cell lymphoma. The objective of the study is to determine the effect of mavrilimumab on the safety of Yescarta. Preclinical evidence shows the potential for interruption of granulocyte macrophage colony stimulating factor (GM-CSF) signaling to disrupt chimeric antigen receptor T (CAR T) cell-mediated inflammation …

Biotech

Global Gynecology Partnering Deal Trends, Players and Financials Directory 2019: Deals Signed Between the World’s Pharmaceutical and Biotechnology Companies | Globe Newswire | 12/4/2019

… 2014-2019: Deal trends, players and financials provides the full collection of Gynecology disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Most of the deals included within the report occur when a … Pharma Genea Biomedx Genoma Genome Medical German Cancer Research Center Gilead Sciences GlaxoSmithKline GOG Foundation Golden Valley Development Good Start Genetics Grunenthal Guided Therapeutics Gynica Halt Medical Hammock Pharmaceuticals HealthNet Helix Helix BioPharma Hologic Hookipa …

Gilead’s converting Truvada PrEP users to Descovy faster than expected: analyst | FiercePharma | 12/4/2019

by Angus Liu Dec 3, 2019 12:13pm In just two months since Descovy’s FDA PrEP approval, Gilead has converted about 10% of Truvada patients to the new drug, IQVIA weekly scripts suggest. (Gilead) One big … doctors and patients to use the new version. The Big Biotech recently detailed data from the phase 3 Discover trial, showing significantly better bone mineral density and renal safety outcomes for Descovy patients than for …

Food and Drug Administration

First Edition: December 4, 2019 | Kaiser Health News | 12/4/2019

… government plans to distribute the drugs for pre-exposure prophylaxis, or PrEP, that were promised in May by the drugmaker Gilead Sciences. (McNeil, 12/3) The Associated Press: Health Program Offers Free HIV Prevention Drug To … closer to confirming President Donald Trump’s nominee to lead the Food and Drug Administration, the agency responsible for combating a recent wave of underage vaping. The Senate’s health committee voted 18-5 to advance the nomination …

Robert Gehrke: These Utahns are working to make sure the terror of the AIDS epidemic remains in the past - The Salt Lake Tribune | 12/4/2019

… treatments have improved, huge strides have also been made on preventing the spread of the virus. In 2012, the U.S. Food and Drug Administration approved a medication that reduces the transmission of HIV through sex … of the daily pills costs about $7 to make, but Gilead Sciences, which has patented the drug, charges about $1,800, putting it out of reach for the uninsured. (The federal government is suing Gilead, alleging …

Medicaid

200,000 Uninsured Americans to Get Free H.I.V.-Prevention Drugs | 12/4/2019

… government plans to distribute the drugs for pre-exposure prophylaxis, or PrEP, that were promised in May by the drugmaker Gilead Sciences. PrEP describes a strategy of preventing infection with H.I.V. by taking a single … federal government is supplying PrEP to patients not enrolled in Medicaid, the Veterans Health Administration or any other federal health program. Under the new program, any patient who lacks health insurance, has had a recent …

First Edition: December 4, 2019 | Kaiser Health News | 12/4/2019

… government plans to distribute the drugs for pre-exposure prophylaxis, or PrEP, that were promised in May by the drugmaker Gilead Sciences. (McNeil, 12/3) The Associated Press: Health Program Offers Free HIV Prevention Drug To … those who don’t have health insurance or are ineligible for Medicaid. (Kounang, 12/3) The Washington Post: Trump Administration Pushes Efforts To Wipe Out HIV Amid Stalled Progress Only 40 percent of U.S. adults have ever …

BioCryst

Could These 5 Stocks Benefit From the Coronavirus Outbreak? | The Motley Fool | 2/10/2020

BioCryst Pharmaceuticals ( NASDAQ:BCRX ) , Gilead Sciences ( NASDAQ:GILD ) , Inovio Pharmaceuticals ( NASDAQ:INO ) , Moderna, Inc. ( NASDAQ:MRNA ) , and Novavax ( NASDAQ:NVAX ) could all make big moves this week on the coronavirus threat. Here’s what investors need to know right now. Image source: Getty Images. BioCryst: The moment may have already passed BioCryst’s tie-in to the coronavirus epidemic is its broad-based antiviral medication galidesivir . Galidesivir has reportedly shown activity against …

Sic transit gloria mundi. Latin for what’s happening today. | 2/10/2020

Gilead has an antiviral drug which may cure coronavirus. They’re testing the drug in Wuhan. The Motley Fool suggests investors keep a close eye on biotech stocks: BioCryst Pharmaceuticals (BCRX), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Moderna, Inc. (MRNA), and Novavax (NVAX). You can read Motley Fool’s piece here. I’m not smart enough to gamble on biotech. I’ve lost my shirt far too often in biotech. None of my investments …

National Medical Products Administration

Gilead, Coronavirus, and Major Stock Swings | 2/8/2020

This article originally was published here: https://www.wealthdaily.com/articles/gilead-coronavirus-and-major-stock-swings/94938 A week ago, you couldn’t turn on the television or open up a news app on your phone without … from the promise of a new antiviral drug candidate. China’s National Medical Products Administration this week approved applications by various research facilities to conduct trials evaluating an experimental drug by the name of remdesivir, which …

Possible Cure For Coronavirus Enters Clinical Trials | 2/8/2020

The registration for clinical trials on the antiviral drug Remdesivir has been approved, and the first batch of pneumonia patients infected by the novel coronavirus (2019-nCoV) started taking the drug on Thursday, according to an official Chinese state release. The approval is jointly supported by the Ministry of Science and Technology (MOST), the National Health Commission and the National Medical Products Administration. Remdesivir is a drug developed by Gilead

Eli Lilly

Ligand Reports Fourth Quarter and Full Year 2019 Financial Results | Markets Insider | Business Insider | 2/6/2020

… Gilead, Janssen, Baxter International and Eli Lilly. For more information, please visit www.ligand.com. Follow Ligand on Twitter @Ligand_LGND. Forward-Looking Statements This news release contains forward-looking statements by Ligand that involve risks and uncertainties and reflect Ligand’s judgment as of the date of this release. Words such as “plans,” “believes,” “expects,” “anticipates,” and “will,” and similar expressions, are intended to identify forward-looking statements. These forward-looking statements …

Pharma, Biotech & Diagnostics: 2014-2019 Licensing Deals & Agreements Entered Into by the World’s Leading Life Science Companies | Globe Newswire | 2/6/2020

… Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.The report also includes numerous table and figures that illustrate the trends and activities in licensing deal making since 2014.In addition, a comprehensive appendix is provided organized by licensing company A-Z, stage of development, therapeutic target, technology type and deal type definitions. Each deal title links …

MorphoSys

Stock Analysts’ Price Target Changes for February, 5th (CERN, CMG, DIS, DOX, GILD, LITE, MCHP, MNTA, MOR, NXPI) | 2/6/2020

Gilead Sciences (NASDAQ:GILD) had its target price reduced by Piper Sandler from to . Lumentum (NASDAQ:LITE) had its price target raised by Piper Sandler from to . Microchip Technology (NASDAQ:MCHP) had its price target raised by B. Riley from to . Momenta Pharmaceuticals (NASDAQ:MNTA) had its target price boosted by Piper Sandler from to . MorphoSys (ETR:MOR) was given a €150.00 ($174.42) target price by analysts at Berenberg Bank …

On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors | 2/6/2020

… Gilead, Epizyme, Janssen, Karypharm, Merck, and Morphosys. D. Cunningham reports receiving other commercial research support from Amgen (REAL 3: Trial for the Royal Marsden NHS Foundation Trust), Sanofi (Trial for the Royal Marsden NHS Foundation Trust), Janssen (IMYC Trial: Trial for the Royal Marsden NHS Foundation Trust), Merck (ICONIC/POLEM Trial: Trial for the Royal Marsden NHS Foundation Trust), Merrimack (PLATFORM Trial: Trial for the Royal Marsden NHS Foundation Trust …

Teva Pharmaceutical

STAT Plus: Gilead loses its challenge to a pair of U.S. patents for an HIV prevention pill | 2/5/2020

February 5, 2020 Rich Pedroncelli/AP I n a setback to Gilead Sciences ( GILD ), a federal panel rejected its bid to invalidate a pair of patents owned by the U.S. government for using the Truvada … version will appear later this year under a deal with Teva Pharmaceuticals ( TEVA ). Separately, yet another but related matter is before the patent appeals board. Two months ago, the PreP4All Collaboration filed an emergency petition …

Royalty Rate Trends in Pharma & Biotech Dealmaking, 2014-2019 – Technology Licensed, Royalty Rates, License Fees, Upfront and Milestone Payments | Financial Buzz | 2/4/2020

… including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda … Technion Research and Development Foundation Tetra Bio-Pharma TetraLogic Pharmaceuticals Teva Pharmaceutical Industries Theravance Theravance Biopharma Thorne Research TiGenix Tilray Tiziana Life Sciences Tramorgan Transgene Trellis Bioscience Trevena TTFactor University of Alberta Uppsalagruppen Medical Valeant …

Teva Pharmaceutical

STAT Plus: Gilead loses its challenge to a pair of U.S. patents for an HIV prevention pill | 2/5/2020

February 5, 2020 Rich Pedroncelli/AP I n a setback to Gilead Sciences ( GILD ), a federal panel rejected its bid to invalidate a pair of patents owned by the U.S. government for using the Truvada … version will appear later this year under a deal with Teva Pharmaceuticals ( TEVA ). Separately, yet another but related matter is before the patent appeals board. Two months ago, the PreP4All Collaboration filed an emergency petition …

Royalty Rate Trends in Pharma & Biotech Dealmaking, 2014-2019 – Technology Licensed, Royalty Rates, License Fees, Upfront and Milestone Payments | Financial Buzz | 2/4/2020

… including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda … Technion Research and Development Foundation Tetra Bio-Pharma TetraLogic Pharmaceuticals Teva Pharmaceutical Industries Theravance Theravance Biopharma Thorne Research TiGenix Tilray Tiziana Life Sciences Tramorgan Transgene Trellis Bioscience Trevena TTFactor University of Alberta Uppsalagruppen Medical Valeant …

Teva Pharmaceuticals

STAT Plus: Gilead loses its challenge to a pair of U.S. patents for an HIV prevention pill | 2/5/2020

February 5, 2020 Rich Pedroncelli/AP I n a setback to Gilead Sciences ( GILD ), a federal panel rejected its bid to invalidate a pair of patents owned by the U.S. government for using the Truvada … version will appear later this year under a deal with Teva Pharmaceuticals ( TEVA ). Separately, yet another but related matter is before the patent appeals board. Two months ago, the PreP4All Collaboration filed an emergency petition …

Royalty Rate Trends in Pharma & Biotech Dealmaking, 2014-2019 – Technology Licensed, Royalty Rates, License Fees, Upfront and Milestone Payments | Financial Buzz | 2/4/2020

… contract document. The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others. The report also includes numerous table and figures that illustrate the trends in royalty rates in …

Grifols

Royalty Rate Trends in Pharma & Biotech Dealmaking, 2014-2019 – Technology Licensed, Royalty Rates, License Fees, Upfront and Milestone Payments | Financial Buzz | 2/4/2020

… including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda … Genevant Sciences Genmab Genzyme Gilead Sciences GlaxoSmithKline Goldfinch Bio Gravocore Grifols Halo Labs Health Canada Hefei Life Science Hefei Tianhui Incubation of Technologies Hemogenyx Hoffmann La Roche Ice + Jam Idera Pharmaceuticals Idorsia iMetabolic Biopharma Immugenyx …

Anti-IL5 and anti-IL5R{alpha} therapy for clinically significant bronchiectasis with eosinophilic endotype: a case series | 1/23/2020

… life http://bit.ly/2AZvBLm Footnotes Conflict of interest: J. Rademacher reports grants and personal fees from Bayer Healthcare, Insmed and Grifols, personal fees from MSD Sharp and Dohme, AstraZeneca and Chiesi, outside the submitted work … Ingelheim and Vortex, personal fees and other from Chiesi and Gilead, grants from Polyphor, grants and other from InfectoPharm, other from Abbott, Pfizer, Oxycare, Heinen and Löwenstein, MSD, Vertex, Parion, Cetaxsys, Corbus, GSK, PARI, APOSAN …

MacroGenics

Royalty Rate Trends in Pharma & Biotech Dealmaking, 2014-2019 – Technology Licensed, Royalty Rates, License Fees, Upfront and Milestone Payments | Financial Buzz | 2/4/2020

… including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda … Level Brands LFB Biotechnologies Lifestyle Delivery Systems Ligand Pharmaceuticals Lubrizol Macrogenics MainPointe Mallinckrodt Pharmaceuticals Medicines Patent Pool Foundation MedImmune Medivation Medivir Merck and Co Merck KGaA Merus Mimi’s Rock Moderna Therapeutics Mologen Morgan Stanley MultiCell …

Co-promotion and Co-marketing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics, Worldwide, 2014-2019 | Globe Newswire | 1/28/2020

… including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda … LI Path Loxo Oncology Luqa Pharmaceuticals Luxcel Biosciences Macherey-Nagel Macrogenics Malvern Instruments Mazor Robotics MDxHealth MedHelp Medical Enterprises Distribution Medicines360 MedImmune Medtronic Meiji Seika Menarini Merck and Co Merck KGaA MGC Diagnostics Microsoft Midatech …

United Technologies

Feb 04, 2020 - Excalibur Management Corp Buys Apple Inc, Independent Bank Corp, AvalonBay Communities Inc, Sells Gilead Sciences Inc, BP PLC - GuruFocus.com | 2/4/2020

… Excalibur Management Corp ( Current Portfolio ) buys Apple Inc, Independent Bank Corp, AvalonBay Communities Inc, Union Pacific Corp, Intel Corp, sells Gilead Sciences Inc, BP PLC during the 3-months ended 2019Q4, according to the most … was 0.48%. The holding were 42,675 shares as of . Added: United Technologies Corp ( UTX ) Excalibur Management Corp added to a holding in United Technologies Corp by 40.82%. The purchase prices were between $130.47 and $150.71 …

Feb 04, 2020 - Hikari Power Ltd Buys The Kraft Heinz Co, Vanguard Health Care ETF, ViacomCBS Inc, Sells General Electric Co, Novo Nordisk A/S, Procter & Gamble Co - GuruFocus.com | 2/4/2020

… Health Care ETF, ViacomCBS Inc, Meritor Inc, HP Inc, sells General Electric Co, Novo Nordisk A/S, Procter & Gamble Co, Gilead Sciences Inc, Biogen Inc during the 3-months ended 2019Q4, according to the most … 0.05%. The holding were 9,320 shares as of . Sold Out: United Technologies Corp ( UTX ) Hikari Power Ltd sold out a holding in United Technologies Corp. The sale prices were between $130.47 and $150.71, with an …

SunTrust Banks

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by American International Group Inc. - Ticker Report | 2/10/2020

American International Group Inc. trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and … been the topic of a number of recent research reports. SunTrust Banks initiated coverage on shares of Gilead Sciences in a research report on Tuesday, November 12th. They issued a “hold” rating and a $70.00 …

Ingalls & Snyder LLC Sells 400 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) | 2/9/2020

Ingalls & Snyder LLC Sells 400 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) Posted by Rex Hubbard on Feb 8th, 2020 Tweet Ingalls & Snyder LLC decreased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD … a “hold” rating in a report on Friday, October 25th. SunTrust Banks assumed coverage on Gilead Sciences in a report on Tuesday, November 12th. They set a “hold” rating and a $70.00 price target for …

Zacks Equity Research

The Zacks Analyst Blog Highlights: Exxon Mobil, Chevron, IBM, Gilead and Edwards Lifesciences | 2/7/2020

Read More Hide Full Article For Immediate Release Chicago, IL – February 7, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Exxon Mobil ( XOM - Free Report ) , Chevron ( CVX - Free Report ) , International Business Machines ( IBM - Free Report ) , Gilead Sciences ( GILD - Free Report …

Coronavirus Starting to Weigh on 2020 Q1 Earnings Estimates | Zacks | 2/6/2020

… Also, IBM’s time-consuming business model transition to cloud is a headwind. Other noteworthy reports we are featuring today include Gilead Sciences ( GILD ), Illinois Tool Works ( ITW ) and Edwards Lifesciences ( EW ). More Stock News: This … Sheraz Mian Director of Research Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes …

Zacks Investment Research

The Zacks Analyst Blog Highlights: Exxon Mobil, Chevron, IBM, Gilead and Edwards Lifesciences | 2/7/2020

… featured in the blog include Exxon Mobil ( XOM - Free Report ) , Chevron ( CVX - Free Report ) , International Business Machines ( IBM - Free Report ) , Gilead Sciences ( GILD - Free Report ) and Edwards Lifesciences ( EW - Free Report ) . Here are highlights from … http://www.facebook.com/home.php /pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the …

Will Coronavirus Ignite a Correction? | 2/6/2020

… US markets barely flinched, even opening higher than last Friday’s big sell-off lows. Stoking more confidence is word that Gilead Sciences has an experimental-stage antiviral drug which was originally targeted to treat SARS … be) representative of the performance of all selections made by Zacks Investment Research’s newsletter editors. This free resource is being sent by Zacks.com . We look for investment resources and inform you of these resources, which …

SunTrust Bank

Gilead Sciences (NASDAQ:GILD) Updates FY 2020 After-Hours Earnings Guidance | 2/5/2020

Gilead Sciences (NASDAQ:GILD) updated its FY 2020 After-Hours earnings guidance on Tuesday. The company provided earnings per share guidance of 6.05-6.45 for the period, compared to the Thomson Reuters consensus earnings per share … a hold rating in a report on Friday, October 25th. SunTrust Banks initiated coverage on Gilead Sciences in a report on Tuesday, November 12th. They issued a hold rating and a $70.00 target price on …

Gilead Sciences (NASDAQ:GILD) Releases FY 2020 After-Hours Earnings Guidance - TheOlympiaReport | 2/5/2020

Gilead Sciences (NASDAQ:GILD) updated its FY 2020 After-Hours earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 6.05-6.45 for the period, compared to the Thomson Reuters $7.01. The company … company in a research report on Friday, October 25th. Finally, SunTrust Banks began coverage on shares of Gilead Sciences in a research report on Tuesday, November 12th. They issued a hold rating and a $70.00 …

Vida Ventures

Health tech funding snapshot—Virta Health lands $93M; Andreessen Horowitz invests in Komodo Health | FierceHealthcare | 2/4/2020

Gilead Sciences to pursue its goal of treating or curing autoimmune diseases using patients’ own cells. Kyverna has raised $25 million in series B funding from Gilead, Vida Ventures and Westlake Village BioPartners. Data analytics: Clinical analytics solutions company Covera Health landed $23 million in series B financing, led by Insight Partners, with participation from existing investors, including Prism Ventures. Consumer experience platform: Zipari , an insurance software startup, nabbed $22.5 …

Visa’s $5.3 Billion Acquisition of Plaid Will Send Shockwaves Through the Industry | Fortune | 1/14/2020

… Vida Ventures, Westlake Village BioPartners , and Gilead Sciences (NASDAQ: GILD) . \n– Codagenix, Inc. , a Stony Brook, N.Y.-based clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, raised $20 million in Series B funding. Adjuvant Capital led the round, and was joined by investors including Euclidean Capital and Topspin Partners. \n PRIVATE EQUITY DEALS \n– Midland Industries, a portfolio company of Wynnchurch Capital, acquired Stainless Adapters Inc , a …

Flagship Pioneering

Sandra Horning, M.D. To Join Moderna’s Board of Directors | Business Wire | 2/3/2020

… experience in bringing transformative medicines to patients,” said Noubar Afeyan, Ph.D., Co-Founder and Chairman of Moderna, and CEO of Flagship Pioneering. “Sandra is a true visionary with a highly distinguished career and we believe … lower prices, and serves on the Board of Directors of Gilead Sciences, Inc. (Nasdaq: GILD). Previously she served as Chief Medical Officer and Head of Global Product Development at Genentech/Roche from 2014 to 2019 …

BioSpace Movers & Shakers, Jan. 10 | 1/10/2020

… a head of sales. Hoitt also held sales, marketing and medical affairs leadership roles at Sarepta Therapeutics, Vertex Pharmaceuticals and Gilead Sciences. Zimmer Biomet – Keri P. Mattox was tapped for the newly created position of … Kintai Therapeutics. Mendlein, who currently serves as executive partner at Flagship Pioneering, brings over 23 years of biotech industry expertise to Kintai. Mendlein replaces Jim Gilbert, who has transitioned off of the board. Prior to …

Silicon Valley Bank

World Antibody Drug Conjugates Market, 2019-2030 - Analysis & Outlook by Type of Payload, Type of Linker, Target Indications, Target Antigens, and Technology Providers | Benzinga | 1/23/2020

… de solidarit FTQ Forbius Formex Formosa Laboratories Fortis Therapeutics Fosun Pharma Foundation Medicine F-Prime Capital GamaMabs Pharma Genentech Genmab Gilead Sciences Global Bio Glycotope Glykos Goodwin Biotechnology GP-Pharm GSK GT Biopharma Halozyme Therapeutics … Shanghai Miracogen Shanghai Pharma Shenogen Pharma Shire Siamab Therapeutics Siegfried Silicon Valley Bank Sinopharm Capital Skyline Ventures Sorrento Therapeutics SOTIO Spectrum Pharmaceuticals Spirogen SpringWorks Therapeutics SR One STA Pharmaceutical Starling Ventures Stason Pharmaceuticals Stemcentrx Sun …

Sierra Oncology Announces Reverse Stock Split | PR Newswire | 1/22/2020

Preferred shares issued in recently completed $103M financing to convert to common shares - - Gilead to become shareholder in Sierra in accordance with amendment to Purchase Agreement - VANCOUVER , Jan. 22, 2020 /PRNewswire/ - Sierra Oncology, Inc. (SRRA … 2019, a term loan of $5.0 million was repaid to Silicon Valley Bank. About Sierra Oncology Sierra Oncology is a late stage drug development company focused on advancing targeted therapeutics for the treatment of patients …

Wedbush Securities

Buckley Wealth Management LLC Sells 6,952 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) | 1/17/2020

Buckley Wealth Management LLC trimmed its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 20.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The … after buying an additional 244 shares in the last quarter. Wedbush Securities Inc. grew its position in Gilead Sciences by 17.7% during the fourth quarter. Wedbush Securities Inc. now owns 23,959 shares of the biopharmaceutical …

Biogen Idec

Visiongain Report Offers Transformative Insights on the $11bn Biological Drug API Manufacturing Market | PR Newswire | 12/3/2019

PRNewswire/ – The biological drug API manufacturing market is estimated to grow at a CAGR of 9.5% in the first half of the forecast period. In 2018, Mammalian cell culture systems submarket represents the largest submarket within the biological drug API manufacturing industry . How this 211-page Visiongain report delivers: • Biological Drug API Manufacturing Services market forecast to 2029 • Biological Drug API Manufacturing Services market forecast to 2029 by Expression Systems …

Risk factors for disease progression in idiopathic pulmonary fibrosis | BMJ | 10/25/2019

… Some of the placebo data were presented as an abstract at ATS in 2017. Funding The study was funded by Gilead Sciences, Inc. Competing interests GR has provided consultation for Gilead Sciences, Inc., for this … Genzyme and Veracyte. VC reports personal fees from Actelion, Bayer, Biogen Idec, Boehringer Ingelheim, Gilead Sciences, Inc., GlaxoSmithKline, Merck Sharp and Dohme, Novartis, Pfizer, Roche/InterMune and Sanofi; grants from Actelion, Boehringer Ingelheim, GlaxoSmithKline, Pfizer …

Morgan Stanley

Gilead Sciences, Inc. (NASDAQ:GILD) Given Consensus Recommendation of “Buy” by Analysts | 12/2/2019

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) have been assigned a consensus rating of “Buy” from the twenty-eight brokerages that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock … hold” rating in a research report on Friday, October 25th. Morgan Stanley set a $75.00 target price on Gilead Sciences and gave the stock a “hold” rating in a research report on Friday, October 25th …

Gilead Sciences, Inc. (NASDAQ:GILD) Sees Significant Growth in Short Interest | 12/1/2019

Gilead Sciences, Inc. (NASDAQ:GILD) was the target of a significant growth in short interest in the month of November. As of November 15th, there was short interest totalling 14,920,000 shares, a growth of 7.2 … for the company in a report on Friday, October 25th. Morgan Stanley set a $75.00 price objective on shares of Gilead Sciences and gave the company a “hold” rating in a report on Friday, October …

MD Anderson Cancer Center

First Edition: December 4, 2019 | Kaiser Health News | 12/4/2019

… government plans to distribute the drugs for pre-exposure prophylaxis, or PrEP, that were promised in May by the drugmaker Gilead Sciences. (McNeil, 12/3) The Associated Press: Health Program Offers Free HIV Prevention Drug To … Stephen Hahn, a cancer specialist and medical executive at the MD Anderson Cancer Center in Houston. Several Democrats opposed Hahn for the role, worrying he would not be tough enough tackling the vaping problem among …

Global Gynecology Partnering Deal Trends, Players and Financials Directory 2019: Deals Signed Between the World’s Pharmaceutical and Biotechnology Companies | Globe Newswire | 12/4/2019

… Health Fogarty Institute for Innovation Foresee Pharmaceuticals Fougera Pharmaceuticals Fuji Pharma Genea Biomedx Genoma Genome Medical German Cancer Research Center Gilead Sciences GlaxoSmithKline GOG Foundation Golden Valley Development Good Start Genetics Grunenthal Guided Therapeutics Gynica … Biotechnologies LifeCodexx Lumara Health Lumir Lab Massachusetts General Hospital McKesson MD Anderson Cancer Center MDNA Life Sciences Meda MEDCIS Pathlabs Medical University of South Carolina Medical University South Carolina MediCare International MediGene MedikorPharma MedImmune Medinova …

Kaiser Permanente

HHS Hands Out Free HIV Prevention Drugs. Do You Qualify? | Kaiser Health News | 12/4/2019

… trump-administration-secures-historic-donation-of-billions-of-dollars-in-hiv-prevention-drugs.html” a donation /a from the drugs’ manufacturer, Gilead Sciences. That would cover the drugs for up to 200,000 uninsured individuals each year … J. Kaiser Family Foundation /a which is not affiliated with Kaiser Permanente. /p …

Bonner County Daily Bee - National News, HHS Hands Out Free HIV Prevention Drugs. Do You Qualify? | 12/4/2019

… more than 90%. The medications, Truvada and Descovy, are made possible in part by a donation from the drugs’ manufacturer, Gilead Sciences. That would cover the drugs for up to 200,000 uninsured individuals each year … Henry J. Kaiser Family Foundation which is not affiliated with Kaiser Permanente

Massachusetts General Hospital

Global Gynecology Partnering Deal Trends, Players and Financials Directory 2019: Deals Signed Between the World’s Pharmaceutical and Biotechnology Companies | Globe Newswire | 12/4/2019

… Health Fogarty Institute for Innovation Foresee Pharmaceuticals Fougera Pharmaceuticals Fuji Pharma Genea Biomedx Genoma Genome Medical German Cancer Research Center Gilead Sciences GlaxoSmithKline GOG Foundation Golden Valley Development Good Start Genetics Grunenthal Guided Therapeutics Gynica … Products Lee’s Pharmaceutical LFB Biotechnologies LifeCodexx Lumara Health Lumir Lab Massachusetts General Hospital McKesson MD Anderson Cancer Center MDNA Life Sciences Meda MEDCIS Pathlabs Medical University of South Carolina Medical University South Carolina MediCare International …

Global Gynecology Partnering Deal Trends, Players and Financials Directory 2019: Deals Signed Between the World’s Pharmaceutical and Biotechnology Companies | Benzinga | 12/4/2019

… Health Fogarty Institute for Innovation Foresee Pharmaceuticals Fougera Pharmaceuticals Fuji Pharma Genea Biomedx Genoma Genome Medical German Cancer Research Center Gilead Sciences GlaxoSmithKline GOG Foundation Golden Valley Development Good Start Genetics Grunenthal Guided Therapeutics Gynica … Products Lee’s Pharmaceutical LFB Biotechnologies LifeCodexx Lumara Health Lumir Lab Massachusetts General Hospital McKesson MD Anderson Cancer Center MDNA Life Sciences Meda MEDCIS Pathlabs Medical University of South Carolina Medical University South Carolina MediCare International …

University of Texas MD Anderson Cancer Center

The return of the megamerger | 12/2/2019

… a deal worth $13.4 billion. Amgen pays $2.7 billion for a roughly 20% stake in the Chinese biopharma firm BeiGene. Gilead Sciences pays Galapagos $5.1 billion as part of a 10-year research pact. Novartis … He also has leadership and crisis experience: he steered the University of Texas MD Anderson Cancer Center out of financial and legal trouble, and while he was at the University of Pennsylvania, he took responsibility …

Inaugural STAT Summit Convened 300+ Health Care Leaders | Business Wire | 11/22/2019

… other issues. The event was underwritten by the Pharmaceutical Research and Manufacturers of America (PhRMA), with additional support from the University of Texas MD Anderson Cancer Center, Pfizer, Allogene Therapeutics, Amgen, Alkermes, Astellas, Sanofi, Bayer … plans for the company; Daniel O’Day, chairman and CEO of Gilead Sciences, who addressed the drug maker’s moves into oncology; and Dr. Jeffrey Leiden, CEO of Vertex Pharmaceuticals, who outlined his company’s development of new …

Harvard Medical School

Combination of immunotherapy and VEGF inhibitor improves survival in HCC | 11/22/2019

… 4I. Medical Department, University Medical Cen-ter Mainz, Mainz, Germany, 5Medical Oncology, Gustave Roussy Cancer Center, Villejuif, France, 6Cancer Center, Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, MA, USA, 7Medical Oncology Cen-ter … self): EA Pharma; Honoraria (self), Advisory / Consultancy: Eisai; Honoraria (self): Gilead Sciences; Honoraria (self): Merck Serono; Honoraria (self), Advisory / Consultancy: MSD; Honoraria (self): Novartis; Honoraria (self): Pfizer; Honoraria (self), Research grant / Funding (institution): Taiho Pharmaceutical …

HCA

Nov 15, 2019 - Bellevue Group AG Buys Glaukos Corp, Arvinas Inc, Becton, Dickinson and Co, Sells Celgene Corp, Gilead Sciences Inc, Teladoc Health Inc - GuruFocus.com | 11/15/2019

Gilead Sciences Inc, Teladoc Health Inc, Avedro Inc, Quidel Corp during Bellevue Group AG. As of 2019Q3, Bellevue Group AG owns 209 stocks with a total value of $5.4 billion. These are the details of the buys and sells. New Purchases: ARVN , PACB , MYL , TXG , SDC , HCAT , BIO , XLRN , ZGNX , TEVA , PTLA , JNJ , CRL , MNTA , LVGO , LIN , PAYX , CLX , STML , XLNX , ADMS , Added Positions: IONS , GKOS , AGIO , BDX , ABT , INSM …

Nov 14, 2019 - Franklin Resources Inc Buys Schlumberger, Occidental Petroleum Corp, Barrick Gold Corp, Sells Red Hat Inc, Anadarko Petroleum Corp, Target Corp - GuruFocus.com | 11/14/2019

… CA, based Investment company Franklin Resources Inc ( Current Portfolio ) buys Schlumberger, Occidental Petroleum Corp, Barrick Gold Corp, Chesapeake Energy Corp, Gilead Sciences Inc, sells Red Hat Inc, Anadarko Petroleum Corp, Target Corp, Ford Motor Co … GPL , VET , PBR.A , FCAU , LEA , SIX , RP , NOAH , BAH , FRC , HCA , AMCX , VER , UI , WPX , ALSN , RM , PSX , FIVE , YY , ZTS , PTLA , DOC , REXR , SFM , TWTR , GLPI , VCYT , GRP.U , ALLE , SC , CARA , RVNC , PCTY , SPWH …

Geisinger

First Edition: November 11, 2019 | Kaiser Health News | 11/11/2019

… Drugs? The Taxpayers, U.S. Says After years of prodding by patient advocates, federal officials on Wednesday sued the drug maker Gilead Sciences, charging that it had infringed government patents on the idea of preventing H.I.V … Traced To Contaminated Equipment, Hospital Says The infants at the Geisinger Medical Center in Danville, Pa., neonatal intensive care unit were tiny, with some born 27 weeks premature. In July, some started to get ill …

Press Release Biocartis NV: Biocartis announces H1 2019 results | Globe Newswire | 9/5/2019

… of the Idylla™ MSI test as a companion diagnostic 1 for immuno-oncology therapies, and with Kite Pharma, Inc. (a Gilead Company), aimed at the development of Idylla™ assays that are supportive to Kite’s therapies … placed in the US with the Diagnostic Medicine Institute at Geisinger 3 . End of June 2019, the total installed base amounted to 1,129 Idylla™ instruments. Commercial cartridge volume – H1 2019 commercial cartridge volume amounted to …

Cleveland Clinic

‘It Hurts. Don’t Do It’: What We Heard This Week | 11/8/2019

… the more pleasant surprises.” – Mitchell Warren, executive director of AVAC: Global Advocacy for HIV Prevention, on a federal lawsuit against Gilead Sciences over patents related to HIV prevention medications . “Social media has been extremely weaponized … basic knowledge, can use that.” – Ali Aminian, MD, of the Cleveland Clinic, on a web-based calculator that predicts individualized outcomes after bariatric surgery. 2019-11-08T17:30:00-0500 …

Companies Seek an Innovative Solution to the Growing Cancer Rates | Benzinga | 9/30/2019

… of 9.6% during the forecast period. INmune Bio, Inc. (NASDAQ: INMB ), Celgene Corporation (NASDAQ: CELG ), Merck & Co., Inc. (NYSE: MRK ), Gilead Sciences, Inc. (NASDAQ: GILD ), Pfizer Inc. (NYSE: PFE ) Immunotherapy can be used to treat … DO, Vice Chairman of rheumatic and immunologic disease, at the Cleveland Clinic at the Seventh Annual Basic and Clinical Immunology for the Busy Clinician symposium. “Immunotherapy is now a pillar of cancer treatment — it is …

Cleveland Clinic, Cleveland OH

Companies Seek an Innovative Solution to the Growing Cancer Rates | Benzinga | 9/30/2019

… of 9.6% during the forecast period. INmune Bio, Inc. (NASDAQ: INMB ), Celgene Corporation (NASDAQ: CELG ), Merck & Co., Inc. (NYSE: MRK ), Gilead Sciences, Inc. (NASDAQ: GILD ), Pfizer Inc. (NYSE: PFE ) Immunotherapy can be used to treat … DO, Vice Chairman of rheumatic and immunologic disease, at the Cleveland Clinic at the Seventh Annual Basic and Clinical Immunology for the Busy Clinician symposium. “Immunotherapy is now a pillar of cancer treatment — it is …

HCA Healthcare

Camber Capital Management LLC Buys HCA Healthcare Inc, Gilead Sciences Inc, Mylan NV, Sells … | 8/20/2019

Boston, MA, based Investment company Camber Capital Management LLC ( Current Portfolio ) buys HCA Healthcare Inc, Gilead Sciences Inc, Mylan NV, United Therapeutics Corp, DaVita Inc, sells Global Blood Therapeutics Inc, Biogen Inc, NuVasive Inc, Clovis Oncology Inc, Alexion Pharmaceuticals Inc during the 3-months ended 2019Q2, according to the most recent filings of the investment company, Camber Capital Management LLC. As of 2019Q2, Camber Capital Management LLC owns 30 stocks …

HCA Healthcare Inc (NYSE:HCA) Expected to Announce Quarterly Sales of $12.61 Billion | 8/6/2019

Brokerages expect HCA Healthcare Inc (NYSE:HCA) to report $12.61 billion in sales for the current quarter, Zacks reports. Ten analysts have issued estimates for HCA Healthcare’s earnings. The highest sales estimate is $12.65 billion … Raymond James set a $86.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Tuesday, April 23rd. Barclays set a $24.00 target price on shares …

Aetna

ICER Will Take Different Approach to Assess Short-Term, High-Impact Products | 12/2/2019

… tisagenlecleucel), first approved in August 2017, costs $475,000 or $373,000 depending on the type of cancer it’s used for; and Gilead Sciences, Inc. unit Kite Pharma, Inc.’s Yescarta (axicabtagene ciloleucel), also a CAR-T … OptumRx. CVS Health, which owns CVS Caremark PBM, purchased insurer Aetna late last year in a $69 billion deal, while insurer Cigna finalized its $54 million purchase of Express Scripts Holding Co. in late December …

First Edition: November 7, 2019 | Kaiser Health News | 11/7/2019

… on iPhones and other Apple mobile devices running its iOS operating system. (11/6) The New York Times: Trump Administration Sues Gilead, Maker Of H.I.V.-Prevention Drugs The Trump administration on Wednesday sued Gilead Sciences, a … The Associated Press: CVS Gets A 3Q Booster Shot From Aetna As Revenue Soars CVS Health revenue surged in the third quarter as the drugstore chain and pharmacy benefits manager added health insurance and pushed …

Cigna

ICER Will Take Different Approach to Assess Short-Term, High-Impact Products | 12/2/2019

… tisagenlecleucel), first approved in August 2017, costs $475,000 or $373,000 depending on the type of cancer it’s used for; and Gilead Sciences, Inc. unit Kite Pharma, Inc.’s Yescarta (axicabtagene ciloleucel), also a CAR-T … late last year in a $69 billion deal, while insurer Cigna finalized its $54 million purchase of Express Scripts Holding Co. in late December 2018. Finally, Anthem Inc. is launching its own in-house PBM …

Obscure Model Puts a Price on Good Health – and Drives Down Drug Costs | MSN | 11/4/2019

… Medicare program in the 2010 Affordable Care Act. “This is a cultural issue,” says Steve Miller, chief clinical officer at Cigna Corp., an insurer. “This is America not wanting to put a value on the … radiation therapy for cancer. Its focus shifted in 2013, when Gilead Sciences Inc.’s hepatitis C drug Solvadi-—the first $1,000-a-pill drug—hit the market. ICER found that Solvadi was cost-effective but …

WellCare Health

The 2019 CPA-Zicklin Index of Corporate Political Disclosure and Accountability | 11/12/2019

… Corp.; Dominion Energy Inc.; Edison International; Entergy Corp.; Estee Lauder Companies Inc.; Exelon Corp.; General Electric Co.; General Mills Inc.; Gilead Sciences Inc.; Hartford Financial Services Group Inc.; Honeywell International Inc.; Host Hotels & Resorts Inc … Group Inc.; Unum Group; Visa Inc.; Walgreens Boots Alliance Inc.; WellCare Health Plans, Inc.; and The Williams Companies Inc. Basement-Dwellers And Backsliders The 2019 Index data show 59 companies from the S&P 500 …

Partner Fund Management, L.P. Buys Allergan PLC, Biomarin Pharmaceutical Inc, Gilead Sciences … | 8/20/2019

San Francisco, CA, based Investment company Partner Fund Management, L.P. ( Current Portfolio ) buys Allergan PLC, Biomarin Pharmaceutical Inc, Gilead Sciences Inc, Sarepta Therapeutics Inc, Alibaba Group Holding, sells UnitedHealth Group Inc, Blueprint Medicines Corp, Arena … shares, 3.37% of the total portfolio. Shares added by 22.52% WellCare Health Plans Inc ( WCG ) - 480,244 shares, 3.37% of the total portfolio. Shares added by 44.29% New Purchase: Biomarin Pharmaceutical Inc ( BMRN ) Partner Fund Management …

Donald Trump

Japan finds 41 more cases on ship as virus alarm doctor dies | 2/8/2020

… that President Xi Jinping urged the U.S. to ‘respond reasonably” to the virus outbreak in a phone call with President Donald Trump. Beijing has complained that the U.S. was flying its citizens out of Wuhan … reported. The drug, Remdesivir, is made by U.S. biotech company Gilead Sciences. ___ Yamaguchi reported from Tokyo. Associated Press writer Foster Klug in Yokohama, Japan, contributed to this report …

Anthony Fauci

China Starts Testing an Antiviral Drug in Coronavirus Patients in Collaboration with the USA: Officials | 2/8/2020

Gilead Sciences announced it would collaborate with U.S., Chinese, and other health officials to investigate whether the drug works. Dr. Anthony S. Fauci, the head of the U.S. National Institute of Allergy and Infectious Diseases, said in a news conference that remdesivir tests have “now begun in a randomized controlled trial in two separate trials in China by one of our colleagues,” Dr. Anthony Fauci, said. They’re looking at …

Health Officials Say U.S. Coronavirus Vaccine is Making Good Progress | The Motley Fool | 2/8/2020

… their own, domestic coronavirus vaccine is proceeding along without any hiccups. National Institute of Allergy and Infectious Disease (NIAID) director Anthony Fauci went on to say that the development of a vaccine is proceeding well … Other healthcare giants are working to develop their own treatments. Gilead recently made news when its Ebola drug, remdesivir, almost completely eliminated symptoms in a patient it was tested on. The Chinese government is now …

Tedros Adhanom Ghebreyesus

10 more sick with virus on one of two isolated cruise ships | 2/7/2020

… one where the cruise ship is currently quarantined “ will be shut down. The director-general of the World Health Organization, Tedros Adhanom Ghebreyesus, on Wednesday asked for $675 million to help countries address the expected … The stock price of the drug’s maker, American biotechnology company Gilead Sciences Inc., has enjoyed a boost from word of the trials. A senior health official in Thailand said that ‘at the moment, there is …

George W. Bush

Tamiflu Scandal: Gilead Sciences’ Donald Rumsfeld Connection | 2/7/2020

Gilead Sciences, the company that exclusively produces Tamiflu , be part of the reason that Relenza is taking a back seat in the H1N1 Swine Flu treatment plan? The suggestion of a US government/ Tamiflu conflict of interest is not new . It first surfaced in 2005 when then President George W. Bush pushed for and won $7.1 billion in emergency funding to prepare for an influenza pandemic that was not even …

Refugees: How Trump’s ‘deal of the century’ is doomed to failure | 2/3/2020

… and Taba, the Israeli position fluctuated. At Camp David, the famous presidential retreat in Maryland, then-Israeli chief of staff Gilead Sher wrote that Israeli negotiators understood any agreement allowing refugees to return would involve … the time and centrist politician, had reportedly convinced US President George W. Bush to adopt Israel’s wholesale rejection of the right of return as his own - an uncompromising position US Secretary of State Condoleeza Rice …

Alex Azar

Thursday, February 6, 2020 | Kaiser Health News | 2/6/2020

… patent on Tecfidera, Biogen’s most important multiple sclerosis drug. That patent was not set to expire until 2028. (Feuerstein, 2/5) Gilead Loses Challenge To Two Patents Over An HIV Prevention Pill In a setback to … our health system and will endanger patient privacy.” HHS Secretary Alex Azar has in the past expressed frustration that stakeholders push back fiercely against the rules. In other news at the intersection of health and …

Coronavirus latest: Wuhan patients to start taking antiviral drug | 2/6/2020

… coronavirus patients in Wuhan will start taking the antiviral drug remdesivir on Thursday. Remdesivir, developed by the U.S. pharmaceutical company Gilead and not approved elsewhere in the world, has been greenlighted by the Chinese health … China from Feb. 9. U.S. Health and Human Services Secretary Alex Azar takes questions from reporters at the White House after declaring a public health emergency over the new coronavirus Jan. 31. © Reuters 9:48 a.m …

Bernie Sanders

Debt Rattle February 6 2020 | 2/6/2020

Who Owns The Coronavirus Cure? (SCMP) China has applied to patent a drug candidate being developed by Gilead Sciences as the government rushes to find the cure for the deadly coronavirus, a move that could … By Razor-Thin Margin In Iowa (Pol.) Pete Buttigieg and Bernie Sanders are running neck and neck in the Iowa caucuses with almost all of the votes counted. Buttigieg has 26.23 percent of the state …

Yahoo! News: World News | 2/5/2020

… gonna kick his ass,” a lunch guest quoted the president as predicting.As for his potential Democratic opponents, he said that Bernie Sanders “is the nastiest and the smartest”—a compliment of sorts—and said he … while emphasizing that it is unproven and not available in China.Gilead, the California-based maker of remdesivir, has issued a statement that the company is in “active discussions with researchers and clinicians in the United …

Scott Gottlieb

Thursday, February 6, 2020 | Kaiser Health News | 2/6/2020

… patent on Tecfidera, Biogen’s most important multiple sclerosis drug. That patent was not set to expire until 2028. (Feuerstein, 2/5) Gilead Loses Challenge To Two Patents Over An HIV Prevention Pill In a setback to … over the vaping crisis. They even invoked former FDA Commissioner Scott Gottlieb, who has been vocal in leading the charge against youth vaping. Meanwhile, a nationwide flavor ban is set to go into effect today …

Coronavirus: Why it takes at least a year to make a vaccine | CNBC | 1/31/2020

… a vaccine for the novel virus sooner than expected. “We may have a vaccine in record time,” former FDA Commissioner Scott Gottlieb said. Lawrence Gostin, a professor and faculty director of the O’Neill Institute for … market. In the meantime, local authorities in China are using Gilead Sciences’ antiviral drug Remdesivir, which was tested as a possible treatment during the Ebola outbreak, U.S. health officials said on the call Tuesday. Some …

Nancy Pelosi

China opens new hospitals for coronavirus patients as deaths top 560 amid 28,000 known cases - South Florida Sun Sentinel - South Florida Sun-Sentinel | Chicago Tribune | 2/6/2020

… the world and a crisis inside the country of 1.4 billion. [Most read] Column: Trump impeachment backfires on Democrats, and Nancy Pelosi has a meltdown » The World Health Organization tweeted: “We are deeply saddened by … reported. The drug, Remdesivir, is made by U.S. biotech company Gilead Sciences. Latest Nation & World Investigations into 2020 candidates must be cleared by top Justice Department officials Feb 6, 2020 …

China Applies for Patent for Drug That Could Fight Coronavirus | 2/6/2020

… China Applies for Patent for Drug That Could Fight Coronavirus China has applied for a new patent on an experimental Gilead Sciences Inc. drug that its scientists believe might fight the coronavirus. It has applied … Current State of the Internet Is Flowing With Memes of Nancy Pelosi Ripping President Trump’s Speech at the State of the Union 3 What to Know About Other Impeached Presidents Contact us at …

Melinda Gates

Deaths Top 560; Nations Restrict Travel From China: Virus Update | 2/6/2020

Gilead Sciences Inc. is expected to start testing in China on Thursday. Gates Foundation Pledges $100 Million (9:15 a.m. NY) The Bill & Melinda Gates Foundation said Wednesday it will commit as much as $100 million to bolster the international response to the novel coronavirus. The funding will help strengthen detection, isolation and treatment efforts; protect at-risk populations; and develop vaccines, therapies and diagnostics. The new funding includes the $10 …

Coronavirus death toll in China rises to 560 - TimesKuwait | 2/6/2020

… said a multinational WHO-led team would go to China “soon”. Gates Foundation announce $100m for coronavirus response The Bill & Melinda Gates Foundation has pledged to commit up to $100m for the global response to … treat the outbreak. China lab seeks patent on use of Gilead’s experimental treatment A state-run Chinese research institute has applied for a patent on the use of Gilead Sciences’ experimental US antiviral drug, which …

Elizabeth Warren

Debt Rattle February 6 2020 | 2/6/2020

Who Owns The Coronavirus Cure? (SCMP) China has applied to patent a drug candidate being developed by Gilead Sciences as the government rushes to find the cure for the deadly coronavirus, a move that could … race too close to call, according to The Associated Press. Elizabeth Warren is in third at 18 percent of the state delegate count, followed by Joe Biden at nearly 16 percent and Amy Klobuchar at …

Yahoo! News: World News | 2/5/2020

… a microbiologist agreeing that it is the “most promising drug,” while emphasizing that it is unproven and not available in China.Gilead, the California-based maker of remdesivir, has issued a statement that the company is … a winner based on the initial results, but Massachusetts Sen. Elizabeth Warren, former Vice President Joe Biden and Minnesota Sen. Amy Klobuchar were trailing in the tally of State Delegate Equivalents, according to data released …